Clinical trial NCT03166735: Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
Official title: A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-alcoholic Fatty Liver Disease
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2017-05-25
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH.

To gain further insight into clinical effects of AOC3 inhibition on NASH further exploratory analyses of biomarkers related to NASH and liver fibrosis will be performed. This will include the effect of BI 1467335 on reduction of secondary biomarker endpoints (ALT, AST, AP, γ-GT and CK18 fragments). Safety will be assessed throughout the study to provide key information regarding the use of BI 1467335 in patients with NASH.


Eligibility criteria: Inclusion criteria:

* Clinical evidence of NASH defined as a. histological evidence of NASH (no more than 3 years prior to screening) OR b. clinical imaging results suggestive of NASH (no more than 3 years prior to screening) OR within the screening phase, imaging procedures performed as per local standard) i. evidence of hepatic steatosis \>5% measured by the MRI-PDFF) or assessed as moderate to severe steatosis (raised echogenicity of the liver parenchyma) by ultrasound AND ii. evidence of liver fibrosis defined as mean stiffness \> 3.64 kPa as measured by the MRE protocol or mean stiffness \> 7.2 kPa as measured by ultrasound based transient elastography (Fibroscan®)
* Increased ALT defined as a. ALT \>1.5 ULN at screening and ALT \>1.25 ULN in a local lab within 1 week to 3 months prior screening OR b. Historic ALT \> 1.25 ULN more than 3 months prior to screening and two consecutive ALT \> 1.5xULN must be confirmed at least 1 week apart within the screening period
* Age ≥ 18 and ≤75 years at screening
* BMI ≥25kg/m2 and \<45kg/m2 at screening
* Stable body weight defined as less than 5% change in body weight in the 3 months prior to screening while being treated with the standard of care and not treated with anti-obesity medication at screening.
* Treatment with Antidiabetic concomitant medication including any insulin regimen needs to be stable for 3 months, and treatment with vitamin E needs to be stable for 6 months prior to informed consent and expected to be stable throughout the trial. All other concomitant medication has to be stable for at least 4 weeks prior screening. Concomitant medications taken to treat acute conditions (e.g. headache, sinusitis) for a short period (\< 7 days) are permissible, if not otherwise prohibited.
* For female patients: Women of childbearing potential\* can be randomized after a negative pregnancy test and under adequate contraception with two methods, of which at least one is highly effective, during the trial.\* A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
* Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial.

Exclusion criteria:

* Current or history of significant alcohol consumption (defined as intake of \>210g/week in males and \>140g/week in females on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on investigator judgement.
* Prior participation in an interventional NASH trial 6 months before baseline or 5 times halflife of the investigational drug, whichever is longer.
* Prior or planned bariatric surgery during study conduct, except gastric-band surgery more than 2 years prior to screening (including adjustments) with a stable body weight within the last 12 months.
* Use of drugs historically associated with liver injury, hepatic steatosis or steatohepatitis in the 4 weeks prior to screening.
* History of liver cirrhosis (fibrosis stage 4), or hepatic decompensation (e.g. ascites, hepatic encephalopathy, variceal bleeding, etc.) or history of other forms of chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease, hemochromatosis, A1At deficiency, history of liver transplantation).
* Active known chronic or relevant acute infections, such as HIV (Human Immunodeficiency Virus), \\viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will be performed during screening. Patients with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active infection.
* Solid liver lesions other than haemangiomas.

  -- Suspicion or diagnosis or history of hepatocellular carcinoma (HCC)
* eGFR \<60ml/min/1.73m2 at screening (CKD-EPI formula).
* ALT \>5.0 ULN at screening.
* Platelet count \< 150.000/μL
* Bilirubin level \> ULN (except for known Gilbert´s disease with a conjugated bilirubin of \< 0.3 mg/dL))
* Uncontrolled diabetes defined as an HbA1c ≥9.5% in the 3 months prior to or at screening.
* Diagnosis of a serious or unstable disease including hepatic (other than NASH), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic , psychiatric, immunologic, or hematologic disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected life expectancy of less than 2 years are also excluded.
* Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomisation or planned during study conduct, e.g. hip replacement.
* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
* Previous randomisation in this trial.
* Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).
* Chronic drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study subject or unlikely to complete the trial.
* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
* Patients with Wolff-Parkinson-White Syndrome, baseline QTc \> 450 ms, family history of long QT, or on medication prolonging QT time at screening or planned initiation during the trial.
* Any other clinical condition that, in the opinion of the investigator, would jeopardize patient safety while participating in this clinical trial.

Primary outcomes:
measure: Plasma Amine Oxidase Copper-containing 3 (AOC3) Activity After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
Secondary outcomes:
measure: Percentage of Participants With Drug-related Adverse Events (AEs)
timeFrame: Start of treatment till end of treatment + 28 days, up to 113 days.
measure: Alanine Aminotransaminase (ALT) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
measure: Aspartate Aminotransferase (AST) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
measure: Alkaline Phosphatase (AP) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
measure: Gamma-glutamyltransferase (GGT) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
measure: Caspase-cleaved Cytokeratin 18 (CK-18 Caspase) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
measure: Total Cytokeratin 18 (CK-18 Total) After 12 Weeks of Treatment, Relative to Baseline in Percent
timeFrame: Day 1 (baseline), day 15, 29, 43, 57 and 85 (time t) 24 hours after the last dose of BI 1467335.
Other outcomes:
Locations:
city: Coronado
country: United States
facility: Southern California Research Center
state: California
city: La Jolla
country: United States
facility: University of California San Diego
state: California
city: La Mesa
country: United States
facility: eStudySite
state: California
city: Los Angeles
country: United States
facility: National Research Institute
state: California
city: Los Angeles
country: United States
facility: National Research Institute
state: California
city: San Francisco
country: United States
facility: Quest Clinical Research
state: California
city: Lakewood Ranch
country: United States
facility: Florida Research Institute
state: Florida
city: Miami
country: United States
facility: Genoma Research Group, Inc
state: Florida
city: New Brunswick
country: United States
facility: Rutgers Robert Wood Johnson Medical School
state: New Jersey
city: Manhasset
country: United States
facility: Northwell Health
state: New York
city: Chapel Hill
country: United States
facility: The University of North Carolina at Chapel Hill
state: North Carolina
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Morehead City
country: United States
facility: Diabetes and Endocrinology Consultants, PC
state: North Carolina
city: Dallas
country: United States
facility: Dallas Diabetes and Endocrine Center
state: Texas
city: Live Oak
country: United States
facility: Pinnacle Clinical Research
state: Texas
city: San Antonio
country: United States
facility: American Research Corporation at the Texas Liver Institute
state: Texas
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Edegem
country: Belgium
facility: Edegem - UNIV UZ Antwerpen
city: Gent
country: Belgium
facility: AZ Maria Middelares
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liège
country: Belgium
facility: Centre Hospitalier Universitaire de Liège
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
city: Toronto
country: Canada
facility: Toronto Liver Centre
state: Ontario
city: Lille
country: France
facility: HOP Claude Huriez
city: Paris
country: France
facility: HOP La Pitié Salpêtrière
city: Aachen
country: Germany
facility: Universitätsklinikum Aachen, AöR
city: Frankfurt am Main
country: Germany
facility: Universitätsklinikum Frankfurt
city: Köln
country: Germany
facility: Universitätsklinikum Köln (AöR)
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
city: Mainz
country: Germany
facility: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
city: Würzburg
country: Germany
facility: Universitätsklinikum Würzburg
city: Dublin
country: Ireland
facility: St James's Hospital
city: Amsterdam
country: Netherlands
facility: Amsterdam UMC, Locatie AMC
city: Maastricht
country: Netherlands
facility: Maastricht Universitair Medisch Centrum
city: Nijmegen
country: Netherlands
facility: Radboud Universitair Medisch Centrum
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
city: Malaga
country: Spain
facility: Hospital Virgen de la Victoria
city: Santander
country: Spain
facility: Hospital Universitario Marqués de Valdecilla
city: Sevilla
country: Spain
facility: Hospital Virgen del Rocío
city: Valencia
country: Spain
facility: Hospital General Universitario de Valencia
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital
city: Liverpool
country: United Kingdom
facility: Aintree University Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
city: Stoke on Trent
country: United Kingdom
facility: Royal Stoke University Hospital
Study officials:
References: